Study Compares Safety and Efficacy of Basal Insulin Analogs and NPH Insulin

Understanding Diabetes and Insulin Therapy

A recent study published in JAMA explored the differences in safety and efficacy between basal insulin analogs and NPH insulin. Diabetes is a chronic and progressive condition that affects the pancreas’s ability to regulate blood sugar levels. The disease tends to worsen over time and with age. Despite effective blood sugar management through lifestyle changes and medications, many diabetic patients eventually require insulin therapy.

Basal insulin analogs were formulated to more closely resemble human insulin compared to earlier versions. Theoretically, these analogs should deliver improved clinical outcomes compared to NPH insulin. However, previous studies have produced mixed results regarding the advantages of using basal insulin analogs over NPH insulin. The primary objective of insulin therapy is to enhance patients’ glycated hemoglobin values, a crucial indicator of blood sugar control, while minimizing the risk of hypoglycemia, which can lead to severe consequences.

Given the higher costs associated with basal insulin analogs, it is important to evaluate their benefits and drawbacks.

Study Overview

The observational study published in JAMA aimed to assess the advantages and side effects of basal insulin analogs versus NPH insulin across a large patient cohort. Researchers from the Department of Internal Medicine at Yale University School of Medicine analyzed data from a diabetes registry in Northern California, examining patients who began a new regimen of either basal insulin analog or NPH insulin from 2006 to 2014. The primary focus was to determine how many patients experienced hospital visits or admissions related to hypoglycemia. Additionally, the researchers measured changes in glycated hemoglobin levels between the two insulin treatment groups.

Among those who initiated an insulin regimen, over 23,000 patients started on NPH insulin, while slightly more than 1,900 began with a basal insulin analog. The study found that 39 patients using basal insulin analogs and 354 patients on NPH insulin visited the emergency department or were hospitalized due to hypoglycemic events. It is essential to note that these figures are based on patient reports and may be subject to bias. The actual number of hypoglycemic events could be underestimated, as they do not account for incidents where patients managed low blood sugar at home without seeking medical assistance.

Statistical Analysis and Findings

Due to the diverse patient-specific factors among study participants, the researchers conducted a statistical analysis to adjust for variables that could influence the outcomes. After controlling for factors such as concurrent medication use and prior hypoglycemia-related hospitalizations, the analysis revealed no significant difference in hypoglycemic events between the two insulin groups.

Regarding insulin efficacy, the researchers observed that patients on NPH insulin experienced a statistically significant greater reduction in their glycated hemoglobin levels compared to those on basal insulin analogs. However, while the findings indicate a difference, these variations are not substantial in clinical practice.

Limitations of the Study

Several limitations should be considered when interpreting the study’s results. The data was sourced from a single diabetes registry in Northern California, which may restrict the generalizability of the findings to a broader population. Numerous patient-specific factors could potentially affect the results, and although the researchers attempted to account for these, some influential factors may have been overlooked. Additionally, the reported hypoglycemic events may not accurately reflect real-life occurrences, as some patients may effectively manage low blood sugar independently without requiring medical intervention.

Conclusion

This study evaluated the frequency of hypoglycemic events and the clinical benefits associated with basal insulin analogs compared to NPH insulin. The more expensive basal insulin analogs did not demonstrate clinical superiority over the less costly NPH insulin. To minimize medication costs, patients are encouraged to engage in discussions with their healthcare providers about the risks and benefits of each insulin option, especially considering the significant price difference.

Written by Jessica Caporuscio, PharmD

Reference: Lipska KJ, Parker MM, Moffet HH, et al. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2018.